Ocugen vs Entrada Therapeutics
Entrada Therapeutics is the larger business, with $25.4m of revenue in fiscal 2025 against $4.4m for Ocugen (5.8 times as much). Ocugen grew faster (8.8% against -87.9%). Entrada Therapeutics kept more of each dollar of sales as profit: a net margin of -565.5% against -1537.4%.
| Latest fiscal year | OcugenOCGN, 2025 | Entrada TherapeuticsTRDA, 2025 |
|---|---|---|
| Revenue | $4.4m | $25.4m |
| Revenue growth | 8.8% | -87.9% |
| Net income | −$67.8m | −$144m |
| Operating margin | -1425.7% | -621.1% |
| Net margin | -1537.4% | -565.5% |
| Return on equity | — | -39.1% |
| Free cash flow | −$57.1m | −$130m |
| Cash | $18.6m | $90.4m |
| Total debt | $31.5m | $0 |
| Debt to equity | — | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 116 | 152 |
| Market value | $253m | $185m |
| Price vs our value range | — | — |
| Moat score | 8 (Weak) | — |
| Insider trades, 12 months | 1 buys, 4 sales | 17 buys, 44 sales |